3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Other solid neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Melanoma
105
Skin Neoplasms
17
Neoplasm Metastasis
15
Neoplasms
10
Uveal Melanoma
9
Carcinoma, Renal Cell
9
Carcinoma, Non-Small-Cell Lung
9
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Lymphoma
2
Eye Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Turcot syndrome
1
Sezary Syndrome
1
Sarcoma, Synovial
1
Interventions
pembrolizumab
11
Specimen Handling
4
X-Rays
3
Nivolumab
3
Ipilimumab
3
Immunoglobulin G
3
Biopsy
3
temsirolimus
2
sargramostim
2
epacadostat
2
capivasertib
2
Taxes
2
Paclitaxel
2
Metformin
2
Magnetic Resonance Spectroscopy
2
Disulfides
2
Cyclophosphamide
2
Blood Specimen Collection
2
zimberelimab
1
veliparib
1
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
spartalizumab
1
sonidegib
1
sapanisertib
1
relatlimab
1
pertuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled